Calidi Biotherapeutics, Inc.CLDI
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NYSE American · United States · calidibio.com
Clinical-stage biotech pioneering targeted delivery of genetic medicines via its RedTail enveloped oncolytic virus platform; lead candidate CLD-401 (IND-enabling) targets non-small cell lung cancer and head and neck cancer. A 1-for-16 reverse split takes effect 2026-07-31 (ticker unchanged).
Key ratios
ROA
-98.2%TTM
2025
-109.8%2024
-112.5%2023
-287.3%
ROE
-312.4%TTM
2025
-700.7%
Recent news
Calidi Biotherapeutics Announces $1.2 Million Registered Direct Offering
Calidi Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Calidi Announces Reverse Stock Split, Expected to Begin Trading on a 1-for-16 Split Adjusted Basis on July 31, 2026
Track CLDI in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer